期刊文献+

GC-MS法测定甲磺酸达比加群酯中的致突变杂质

Determination of the contents of mutagenic impurity in Dabigatran Etexilate Mesylate by GC-MS
下载PDF
导出
摘要 目的建立一种气相色谱-质谱联用法(GC-MS)同时测定甲磺酸达比加群酯中甲磺酸甲酯、甲磺酸乙酯和甲磺酸异丙酯的方法。方法采用DB-624色谱柱(30 m×0.25 mm,1.4μm);程序升温:起始温度100℃,以15℃·min^(-1)的速率升温至200℃,再以25℃·min^(-1)的速率升温至240℃;进样口温度为220℃,载气为氦气,流速为1.0 mL·min^(-1),进样量为2.0μL。采集模式为选择离子监测(SIM),离子源温度为230℃。通过内标法进行计算。结果3种甲磺酸酯之间的分离度均大于2.0,甲磺酸甲酯、甲磺酸乙酯、甲磺酸异丙酯的线性回归方程分别为Y=0.0130X+0.0524(r=0.9990)、Y=0.0249X+0.0633(r=0.9993)、Y=0.0188X+0.0906(r=0.9985),均在5.0~120.0 ng·mL^(-1)浓度范围内线性关系良好。检出限为1.5 ng·mL^(-1)(0.15 ppm),定量限为5 ng·mL^(-1)(0.5 ppm)。甲磺酸甲酯、甲磺酸乙酯和甲磺酸异丙酯的平均回收率分别为96.28%、97.91%和95.87%,RSD分别为2.83%、2.93%和1.73%。结论本方法简便、快速、准确、专属性强、灵敏度高,适用于甲磺酸达比加群酯中3种甲磺酸酯的检测。 Objective To establish a method for determination of MMS,EMS and IMS in Dabigatran Etexilate Mesylate by GC-MS.Methods The analysis was carried on an DB-624 column(30 m×0.25 mm,1.4μm).The GC oven temperature was programmed with an initial temperature of 100℃,increasing to 200℃by 15℃·min^(-1),then increasing to 240℃by 25℃·min^(-1).The temperature of the injection port and interface was set at 220℃.Helium was used as the carrier gas;the flow rate was 1.0 mL·min^(-1),and the volume of the injection was 2.0μL.Data acquisition was performed with SIM,and the temperature of the ion source was set at 230℃.Calculated by internal standard method.Results The resolutions of the three mathane sulfonates were greater than 2.0.Linear regression equation of MMS,EMS and IMS was Y=0.0130X+0.0524(r=0.9990),Y=0.0249X+0.0633(r=0.9993),and Y=0.0188X+0.0906(r=0.9985).The linearitis of all were good in the range of 5.0~120.0 ng·mL^(-1).The limit of detection was 1.5 ng·mL^(-1)(0.15 ppm),and the limit of quantification was 5 ng·mL^(-1)(0.5 ppm),respectively.The extractive recovery of MMS,EMS and IMS was 96.28%,97.91%and 95.87%,and the RSD was 2.83%,2.93%and 1.73%,respectively(n=9).Conclusion The method was proved to be simple,accurate,rapid,high sensitivity and good selectivity,and suitable for the determination of the three mathane sulfonates in Dabigatran Etexilate Mesylate.
作者 柏建学 柴发永 范锋 BAI Jianxue;CHAI Fayong;FAN Feng(Shandong Center for Food and Drug Evaluation&Inspection,Jinan 250014,China;Cisen Pharmaceutical Co.,Ltd.,Jining 272073,China)
出处 《药学研究》 CAS 2021年第10期652-655,共4页 Journal of Pharmaceutical Research
  • 相关文献

参考文献4

二级参考文献37

  • 1DE CATERINA R. The current role of anticoagulants in cardiovascular medicine [ J ]. J Cardiovasc Med (Hagerstown) , 2009, 10(8) : 595 -604.
  • 2HART RG, PEARCE LA, AGUILAR MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[ J ]. Ann Intern Med, 2007, 146 (12) : 857 - 867.
  • 3WALLENTIN L, YUSUF S, EZEKOWITZ MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : an analysis of the RE-LY trial [ J ]. Lancet, 2010, 376(9745) : 975 -983.
  • 4BLOMMEL ML, BLOMMEL AL. Dabigatran etexilate: A novel oral direct thrombln inhibitor [ J ]. Am J Health Syst Pharra, 2011, 68(16) : 1506 -1519.
  • 5STANGIER J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate[ J]. Clin Pharmacokinet, 2008, 47 (5) : 285 - 295.
  • 6BAETZ BE, SPINLER SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases[ J]. Pharmacotherapy, 2008, 28(11) : 1354 - 1373.
  • 7ABRAHAM ME, MARCY TR. Warfarin versus dabigatran: com- paring the old with the new[J]. Consult Pharm, 2012, 27(2) : 121 - 124.
  • 8STANGIER J, CLEMENS A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor [ J ]. Clin Appl Thromb Hemost, 2009, 15 (Suppl 1) : S9 - S16.
  • 9BLECH S, EBNER T, LUDWIG-SCHWELLINGER E, et al.The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans[J]. Drug Metab Dispos, 2008, 36 (2) : 386 -399.
  • 10VILES-GONZALEZ JF, REDDY VY, PETRU J, et al. Incomplete occlusion of the left atrial appendage with the percutaneous left atrial appendage transcatheter occlusion device is not associated with increased risk of stroke [ J ]. J Interv Card Electrophysiol, 2012, 33(1): 69-75.

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部